Candel Therapeutics and Cullinan Therapeutics are making significant strides in the development of new treatments for lung cancer. Candel’s viral immunotherapy, CAN-2409, has shown promising results in a phase 2a trial, achieving a prolonged median overall survival of 24.5 months in advanced NSCLC patients. Meanwhile, Cullinan’s EGFR ex20ins inhibitor, zipalertinib, has met its primary endpoint in a phase 2b trial, demonstrating a positive overall response rate in patients with NSCLC harboring EGFR exon 20 insertion mutations. These breakthroughs offer new hope for patients with lung cancer and highlight the potential for innovative treatments to improve patient outcomes.
Forecast for 6 months: Expect increased investment in lung cancer research and development, with several biotech companies announcing new partnerships and collaborations to accelerate the development of innovative treatments.
Forecast for 1 year: Candel Therapeutics is expected to submit a Biologics License Application for CAN-2409 in prostate cancer, marking a significant milestone in the development of this promising treatment. Additionally, Cullinan Therapeutics will likely initiate a phase 3 trial for zipalertinib, further solidifying its position as a leader in the treatment of NSCLC.
Forecast for 5 years: The lung cancer treatment landscape is expected to undergo a significant transformation, with the approval of several new treatments, including immunotherapies and targeted therapies. Candel Therapeutics and Cullinan Therapeutics are likely to be at the forefront of this transformation, with their innovative treatments offering new hope for patients with lung cancer.
Forecast for 10 years: By 2033, lung cancer is expected to become a manageable disease, with treatments available that can significantly improve patient outcomes. Candel Therapeutics and Cullinan Therapeutics will likely continue to play a leading role in the development of these treatments, driving innovation and progress in the field of lung cancer research.
